Caris Life Sciences financials
$31.55−0.63%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q4 '15 Jun 30 | Q3 '15 Mar 31 | Q2 '15 Dec 31 | Q1 '15 Sep 30 | Q4 '14 Jun 30 | Q3 '14 Mar 31 | Q2 '14 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $263.7M | $216.2M | $292.9M | $216.8M | $181.4M | $865.5M | $817.8M | $815.4M | $814.7M | $905.7M | $900.4M | $894.2M |
| Gross profit | $179.6M | $141.3M | $220.9M | $147.5M | $113.7M | $298.1M | $275.0M | $268.7M | $278.1M | $293.1M | $294.6M | $287.5M |
| Gross margin | 68.1% | 65.4% | 75.4% | 68.0% | 62.7% | 34.4% | 33.6% | 33.0% | 34.1% | 32.4% | 32.7% | 32.2% |
| Operating income | $26.9M | $5.3M | $88.4M | $32.6M | -$18.0M | $75.1M | $53.7M | $47.5M | $60.1M | $69.2M | $60.5M | $66.5M |
| Net income | -$637.0K | -$510.0K | $82.0M | $24.3M | -$517.2M | $41.4M | $29.0M | $24.6M | $31.1M | $36.5M | $30.8M | $35.0M |
| Net margin | −0.2% | −0.2% | 28.0% | 11.2% | −285.1% | 4.8% | 3.6% | 3.0% | 3.8% | 4.0% | 3.4% | 3.9% |
| Diluted EPS | $0.00 | $0.00 | $0.30 | $0.08 | $-7.97 | $1.68 | $1.18 | $1.01 | $1.29 | $1.49 | $1.19 | $1.38 |
| EBITDA | $33.5M | $10.3M | $92.7M | $37.5M | -$11.6M | $75.1M | $69.8M | $64.3M | $77.3M | $69.2M | $78.4M | $82.7M |
| Operating cash flow | $28.5M | $32.9M | $44.8M | $62.4M | $7.3M | $36.5M | $97.1M | -$18.5M | $111.7M | $52.3M | $101.7M | $17.3M |
| Free cash flow | $6.4M | $22.5M | $39.7M | $55.3M | $5.9M | $32.1M | $91.3M | -$22.4M | $108.4M | $48.7M | $97.2M | $13.2M |
| Diluted shares | 282.9M | 282.6M | 271.1M | 297.2M | 64.9M | 24.4M | 24.5M | 24.3M | 24.1M | 25.2M | 26.0M | 25.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Jun 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $690.9M | $821.1M | $797.8M | $754.7M | $720.4M | $35.4M |
| Short-term investments | $102.2M | $2.3M | $2.3M | $2.3M | $2.2M | — |
| Total debt | $393.2M | $381.6M | $379.0M | $376.5M | $373.7M | $1.06B |
| Total assets | $1.23B | $1.16B | $1.13B | $984.6M | $955.1M | $3.24B |
| Total liabilities | $637.9M | $568.9M | $548.4M | $506.2M | $502.2M | $1.76B |
| Shareholders' equity | $591.7M | $593.5M | $577.3M | $478.4M | $452.9M | $1.48B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology